Virpax® Pharmaceuticals to Present at 2024 BIO International Convention
Virpax Pharmaceuticals (NASDAQ: VRPX), a firm developing non-addictive treatments for pain, PTSD, CNS disorders, and viral barriers, will present at the 2024 BIO International Convention in San Diego. CEO Gerald W. Bruce will deliver a corporate presentation on June 3rd at 4:00 p.m. PT in Theater 3. The Virpax team will also host meetings from June 3rd through the 5th. Interested parties can schedule meetings via the BIO International meeting platform or by contacting betsy.brod@affinitygrowth.com.
- Virpax's presentation at a major industry convention could increase visibility and attract investor interest.
- Participation in the BIO International Convention may lead to strategic partnerships and collaborations.
- CEO Gerald W. Bruce's presentation may provide updates on the company's pipeline and future plans.
- The press release lacks specific updates on clinical trials or product development, which may raise concerns among investors.
- No financial data or recent performance metrics are provided, leaving investors without clear indicators of the company's current financial health.
Event: Virpax Presentation at the 2024 BIO International Convention
Date: Monday, June 3rd
Time: 4:00 p.m. PT
Location: Theater 3
Mr. Bruce and team members will host meetings from June 3rd through the 5th. To schedule a meeting, please submit a meeting request through the BIO International meeting platform or contact betsy.brod@affinitygrowth.com.
About Virpax Pharmaceuticals
Virpax is developing branded, non-addictive pain management products candidates using its proprietary technologies to optimize and target drug delivery. Virpax is initially seeking FDA approval for two prescription drug candidates that employ two different patented drug delivery platforms. Probudur™ is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain and Envelta™ is an intranasal molecular envelope enkephalin formulation being developed to manage severe pain, including post cancer pain. Virpax is also using its intranasal Molecular Envelope Technology (MET) to develop one other prescription product candidate, NobrXiol™, which is being developed for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of rare pediatric epilepsy. Virpax has competitive cooperative research and development agreements (CRADAs) for two of its prescription drug candidates, one with the National Institutes of Health (NIH) and one with the Department of Defense (DOD). Virpax is also seeking approval of two nonprescription product candidates: AnQlar, which is being developed to inhibit viral replication caused by influenza or SARS-CoV-2, and Epoladerm™, which is a topical diclofenac spray film formulation being developed to manage pain associated with osteoarthritis. For more information, please visit virpaxpharma.com and follow us on Twitter, LinkedIn and YouTube.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240529164265/en/
Investor Relations:
Betsy Brod
Affinity Growth Advisors
Betsy.brod@affinitygrowth.com
(917) 923-8541
Media:
Robert Cavosi
RooneyPartners
rcavosi@rooneypartners.com
(646) 638-9891
Source: Virpax Pharmaceuticals
FAQ
When is Virpax presenting at the 2024 BIO International Convention?
Where is the 2024 BIO International Convention being held?
Who will deliver the presentation for Virpax at the BIO International Convention?
What is the stock symbol for Virpax Pharmaceuticals?
How can meetings be scheduled with Virpax at the BIO International Convention?
